Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients
Public ClinicalTrials.gov record NCT03623243. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Exploring the Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Patients With Advancing Forms of Relapsing Multiple Sclerosis: A 6-month Open Label, Multi- Center Phase IIIb Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To assess safety and tolerability of patients converting from approved Relapsing Multiple Sclerosis (RMS) Disease Modifying Therapies (DMTs) to siponimod.
Study identification
- NCT ID
- NCT03623243
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 185 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 14, 2019 (Actual)
- Primary completion
- Jul 6, 2022 (Actual)
- Completion
- Jul 6, 2022 (Actual)
- Last update posted
- Jun 20, 2024
2019 – 2022
United States locations
- U.S. sites
- 54
- U.S. states
- 23
- U.S. cities
- 52
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Birmingham | Alabama | 35209 | — |
| Novartis Investigative Site | Cullman | Alabama | 35058 | — |
| Alabama Neurology Associates | Homewood | Alabama | 35209 | — |
| Novartis Investigative Site | Tucson | Arizona | 85718 | — |
| Novartis Investigative Site | Fresno | California | 93710 | — |
| Novartis Investigative Site | Fullerton | California | 92835 | — |
| Novartis Investigative Site | Irvine | California | 92617 | — |
| Novartis Investigative Site | Colorado Springs | Colorado | 80907 | — |
| Novartis Investigative Site | Denver | Colorado | 80209 | — |
| Novartis Investigative Site | Fort Collins | Colorado | 80528 | — |
| Novartis Investigative Site | Boca Raton | Florida | 33487 | — |
| Novartis Investigative Site | Bradenton | Florida | 34205 | — |
| MS & Neuromuscular Center of Excellence | Clearwater | Florida | 33761 | — |
| Novartis Investigative Site | Maitland | Florida | 32751 | — |
| Novartis Investigative Site | Miami | Florida | 33136 | — |
| Novartis Investigative Site | Ocala | Florida | 34471 | — |
| Novartis Investigative Site | Oldsmar | Florida | 34677 | — |
| Novartis Investigative Site | Orlando | Florida | 32806 | — |
| Novartis Investigative Site | Ormond Beach | Florida | 32174 | — |
| Novartis Investigative Site | Sarasota | Florida | 34243 | — |
| Novartis Investigative Site | Sunrise | Florida | 33351 | — |
| Novartis Investigative Site | Tampa | Florida | 33612 | — |
| Novartis Investigative Site | Vero Beach | Florida | 32960 | — |
| Novartis Investigative Site | Flossmoor | Illinois | 60422 | — |
| Novartis Investigative Site | Indianapolis | Indiana | 46256 | — |
| Novartis Investigative Site | Lexington | Kentucky | 40503 | — |
| Novartis Investigative Site | Lexington | Kentucky | 40509 | — |
| Novartis Investigative Site | Lexington | Kentucky | 40513 | — |
| Novartis Investigative Site | Rockville | Maryland | 20854 | — |
| Novartis Investigative Site | Clinton Township | Michigan | 48035 | — |
| Novartis Investigative Site | St Louis | Missouri | 63110 | — |
| Novartis Investigative Site | Las Vegas | Nevada | 89128 | — |
| Novartis Investigative Site | Hackensack | New Jersey | 07601 | — |
| Novartis Investigative Site | Asheville | North Carolina | 28806 | — |
| Novartis Investigative Site | Greensboro | North Carolina | 27405 | — |
| Novartis Investigative Site | Raleigh | North Carolina | 27607 | — |
| Novartis Investigative Site | Cincinnati | Ohio | 45219 | — |
| Novartis Investigative Site | Cleveland | Ohio | 44106-5028 | — |
| Novartis Investigative Site | Oklahoma City | Oklahoma | 73104 | — |
| Abington Neurological Associates, Ltd | Abington | Pennsylvania | 19001 | — |
| Novartis Investigative Site | Philadelphia | Pennsylvania | 19141 | — |
| Novartis Investigative Site | Willow Grove | Pennsylvania | 19090 | — |
| Novartis Investigative Site | Greer | South Carolina | 29650 | — |
| Novartis Investigative Site | Old Point Station | South Carolina | 29707 | — |
| Novartis Investigative Site | Cordova | Tennessee | 38018 | — |
| Novartis Investigative Site | Johnson City | Tennessee | 37604 | — |
| Novartis Investigative Site | Round Rock | Texas | 78681 | — |
| Novartis Investigative Site | San Antonio | Texas | 78258 | — |
| Novartis Investigative Site | Falls Church | Virginia | 22043 | — |
| Novartis Investigative Site | Kirkland | Washington | 98034 | — |
| Novartis Investigative Site | Seattle | Washington | 98122 | — |
| Novartis Investigative Site | Spokane | Washington | 99202 | — |
| Novartis Investigative Site | Tacoma | Washington | 98405 | — |
| Novartis Investigative Site | Waukesha | Wisconsin | 53188 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03623243, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 20, 2024 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03623243 live on ClinicalTrials.gov.